First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, Jean-Charles; Tan, Daniel S W; Chiari, Rita; Wu, Yi-Long; Paz-Ares, Luis; Wolf, Juergen; Geater, Sarayut L; Orlov, Sergey; Cortinovis, Diego; Yu, Chong-Jen; Hochmair, Maximillian; Cortot, Alexis B; Tsai, Chun-Ming; Moro-Sibilot, Denis; Campelo, Rosario G; McCulloch, Tracey; Sen, Paramita; Dugan, Margaret; Pantano, Serafino; Branle, Fabrice; Massacesi, Cristian; de Castro, Gilberto

doi:10.1016/s0140-6736(17)30123-x

Cited by 1,151Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Soria, Jean-Charles, Tan, Daniel S W, Chiari, Rita, Wu, Yi-Long, Paz-Ares, Luis, Wolf, Juergen, Geater, Sarayut L, Orlov, Sergey, Cortinovis, Diego, Yu, Chong-Jen, Hochmair, Maximillian, Cortot, Alexis B, Tsai, Chun-Ming, Moro-Sibilot, Denis, Campelo, Rosario G, McCulloch, Tracey, Sen, Paramita, Dugan, Margaret, Pantano, Serafino, Branle, Fabrice, Massacesi, Cristian, de Castro, Gilberto·2017·The Lancet

DOI 10.1016/s0140-6736(17)30123-x

Open this paper in CoChat — free account

Abstract

Background The efficacy of ceritinib in patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC) is not known. We assessed the efficacy and safety of ceritinib versus platinum-based chemotherapy in these patients. Methods This randomised, open-label, phase 3 study in untreated patients with stage IIIB/IV ALK-rearranged non-squamous NSCLC was done in 134 centres across 28 countries. Eligible patients were assigned via interactive response technology to oral ceritinib 750 mg/day or platinum-based chemotherapy ([cisplatin 75 mg/m 2 or carboplatin AUC 5-6 plus pemetrexed 500 mg/m 2 ] every 3 weeks for four cycles followed by maintenance pemetrexed); randomisation was stratified by World Health Organization performance status (0 vs 1-2), previous neoadjuvant or adjuvant chemotherapy, and presence of brain metastases as per investigator's assessment at screening. Investigators and patients were not masked to treatment assignment. The primary endpoint was blinded independent review committee assessed progression-free survival, based on all randomly assigned patients (the full analysis set). Efficacy analyses were done based on the full analysis set. All safety analyses were done based on the safety set, which included all patients who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT01828099. Findings Between Aug 19, 2013, and May 11, 2015, 376 patients were randomly assigned to ceriti…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(17)30123-x

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Duration of response, progression-free survival, and overall survival are even more variable across these trials.
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [25]

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., Serwatowski, P., Gatzemeier, U., Digumarti, R., Zukin, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0375 · Cited by 3,203
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citation
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Shaw, A. T., Yeap, B. Y., Mino-Kenudson, M. A., Digumarthy, S. R., Costa, D. B., Heist, R. S., Solomon, B., Stubbs, H., Admane, S., McDermott, U., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6993 · Cited by 1,873
Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311107 · Cited by 1,495
Self-citation
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
Katayama, R., Shaw, A. T., Khan, T. M., Mino-Kenudson, M. A., Solomon, B., Halmos, B., Jessop, N. A., Wain, J. C., Yeo, A. T., Benes, C. H., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003316 · Cited by 1,337
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, T., Brodowicz, T., Zielinski, C., Kim, J. H., Krzakowski, M., Laack, E., Wu, Y.-L., Bover, I., Begbie, S., Tzekova, V., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61497-5 · Cited by 1,111
Self-citation
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 923
The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer
Friboulet, L., Li, N., Katayama, R., Lee, C. C., Gainor, J. F., Crystal, A., Michellys, P., Awad, M. M., Yanagitani, N., Kim, S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0846 · Cited by 863
PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Paz-Ares, L. G., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.1102 · Cited by 624
Self-citation
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Paz-Ares, L., de Marinis, F., Dediu, M., Thomas, M., Pujol, J.-L., Bidoli, P., Molinier, O., Sahoo, T. P., Laack, E., Reck, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70063-3 · Cited by 610
Self-citation
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Kim, D.-W., Mehra, R., Tan, D. S. W., Felip, E., Chow, L. Q. M., Camidge, D. R., Vansteenkiste, J., Sharma, S., De Pas, T., Riely, G. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00614-2 · Cited by 471
Self-citation
Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial
Gettinger, S. N., Bazhenova, L. A., Langer, C. J., Salgia, R., Gold, K. A., Rosell, R., Shaw, A. T., Weiss, G. J., Tugnait, M., Narasimhan, N. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30392-8 · Cited by 356
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer: Results From PROFILE 1014
Solomon, B., Cappuzzo, F., Felip, E., Blackhall, F. H., Costa, D. B., Kim, D., Nakagawa, K., Wu, Y.-L. L. C., Mekhail, T. M., Paolini, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5888 · Cited by 267
Self-citation
Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed
Camidge, D. R., Kono, S. A., Lu, X. J. D., Okuyama, S., Barón, A. E., Oton, A. B., Davies, A. M., Varella‐Garcia, M., Franklin, W. A., & Doebele, R. C. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31820cf053 · Cited by 239
Targeting brain metastases in ALK-rearranged non-small-cell lung cancer
Zhang, I., Zaorsky, N. G., Palmer, J. D., Mehra, R., & Lu, J. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00013-3 · Cited by 192
Anaplastic Lymphoma Kinase Translocation: A Predictive Biomarker of Pemetrexed in Patients with Non-small Cell Lung Cancer
Lee, J., Kim, T. M., Lee, S., Kim, D., Kim, S., Jeon, Y., Chung, D. H., Kim, W. H., Kim, Y. T., Yang, S.-C., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182208fc2 · Cited by 160
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
Scagliotti, G. V., Kortsik, C., Dark, G. G., Price, A., Manegold, C., Rosell, R., O'Brien, M. E. R., Peterson, P. M., Castellano, D., Selvaggi, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.690.11.2 · Cited by 139
Self-citation
Clinical characteristics of ALK+ NSCLC patients (pts) treated with crizotinib beyond disease progression (PD): Potential implications for management.
Otterson, G. A., Riely, G. J., Shaw, A. T., Crinò, L., Kim, D., Martins, R. G., Salgia, R., Zhou, C., Solomon, B., Wilner, K. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.7600 · Cited by 29
Phase 2 study of ceritinib in ALKi-naïve patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC): Whole body responses in the overall pt group and in pts with baseline brain metastases (BM)
Felip, E., Orlov, S., Park, K., Yu, C., Tsai, C., Nishio, M., Dols, M. C., McKeage, M. J., Su, W., Mok, T. S. K., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw383.03 · Cited by 26
Self-citation
Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase
Hong, Y., Passos, V. Q., Huang, P., & Lau, Y. Y. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.849 · Cited by 24
MA07.03 Alectinib (ALC) versus Crizotinib (CRZ) in ALK-Positive Non-Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J-ALEX)
Kim, Y., Hida, T., Nokihara, H., Kondo, M., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.427 · Cited by 9
P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC
Dziadziuszko, R., Kim, D., Bearz, A., Laurie, S. A., McKeage, M. J., Park, K., Kim, S., Passos, V. Q., Osborne, K., Lau, Y. Y., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.1666 · Cited by 7
Randomised, Multicentre, Phase Iii, Open-Label Study of Alectinib Vs Crizotinib in Treatment-Naïve Anaplastic Lymphoma Kinase (Alk)-Positive Advanced Nsclc (Alex Study)
Peters, S., Mok, T. S. K., Pérol, M., Ou, S. I., Rosell, R., Bāra, I., Henschel, V., & Camidge, D. R. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu349.113 · Cited by 2
Lung cancer
Dziadziuszko, R., Baumann, M. A., Mitsudomi, T., Kerr, K. M., Peters, S., & Zimmermann, S. (2016) · Oxford University Press eBooks · doi:10.1093/med/9780199656103.003.0046 · Cited by 2

Flagged first, then by citations

1 of the 26 references couldn’t be matched to a known paper.

Sorted by citations

The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Mok, T. S. K., Wu, Y.-L. L. C., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., de Castro, G., Srimuninnimit, V., Лактионов, К. К., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,357
Self-citation
Lung cancer
Thai, A. A., Solomon, B., Sequist, L. V. D., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,688
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704795 · Cited by 2,527
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Dávila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,268
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0025 · Cited by 1,430
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
Planchard, D., Smit, E. F., Groen, H. J. M., Mazières, J., Besse, B., Helland, Å., Giannone, V., D'amelio, A. M., Zhang, P., Mookerjee, B., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30679-4 · Cited by 1,373
Non–Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology
Ettinger, D. S., Wood, D. E., Aisner, D. L., Akerley, W., Bauman, J. R., Chirieac, L. R., D’Amico, T. A., DeCamp, M. M., Dilling, T. J., Dobelbower, M. C., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0050 · Cited by 1,315
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
Mosele, F., Remón, J., Mateo, J., Westphalen, C. B., Barlési, F., Lolkema, M. P., Normanno, N., Scarpa, A., Robson, M. E., Meric‐Bernstam, F., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.07.014 · Cited by 1,230
Brain metastases
Achrol, A. S., Rennert, R. C., Anders, C. K., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,201
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Bauer, T. M., de Marinis, F., Felip, E., Goto, Y., Liu, G., Mazières, J., Kim, D., Mok, T. S. K., Polli, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2027187 · Cited by 1,139
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Skoulidis, F., & Heymach, J. V. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0179-8 · Cited by 1,019
Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer
Camidge, D. R., Kim, H. R., Ahn, M.-J., Yang, J. C.-H., Han, J.-Y., Lee, J.-S., Hochmair, M. J., Li, J. Y.-C., Chang, G.-C., Lee, K. H., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810171 · Cited by 980
Self-citation
Non–Small Cell Lung Cancer, Version 4.2024
Riely, G. J., Wood, D. E., Ettinger, D. S., Aisner, D. L., Akerley, W., Bauman, J. R., Bharat, A., Bruno, D. S., Chang, J. Y., Chirieac, L. R., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2204.0023 · Cited by 919
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.009 · Cited by 909
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Mateo, J., Chakravarty, D., Dienstmann, R., Jezdic, S., González-Pérez, A., López-Bigas, N., Ng, C. K. Y., Bedard, P. L., Tortora, G., Douillard, J.-Y., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy263 · Cited by 858
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study
Solomon, B. J., Besse, B., Bauer, T. M., Felip, E., Soo, R. A., Camidge, D. R., Chiari, R., Bearz, A., Lin, C.-C., Gadgeel, S. M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30649-1 · Cited by 791
Self-citation
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group
Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
Tan, A. C., & Tan, D. S. W. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01626 · Cited by 799
Self-citation
Precision Diagnosis and Treatment for Advanced Non–Small-Cell Lung Cancer
Reck, M., & Rabe, K. F. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703413 · Cited by 736
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
Mok, T. S. K., Camidge, D. R., Gadgeel, S. M., Rosell, R., Dziadziuszko, R., Kim, D.-W., Pérol, M., Ou, S.-H. I., Ahn, J. S., Shaw, A. T., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.478 · Cited by 695
Non‐small cell lung cancer in China
Chen, P., Liu, Y., Wen, Y., & Zhou, C. (2022) · 癌症：英文版 · doi:10.1002/cac2.12359 · Cited by 682
Non-small-cell lung cancer
Hendriks, L. E. L., Remón, J., Finn, C. F., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 690
Self-citation
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
Shaw, A. T., Felip, E., Bauer, T. M., Besse, B., Navarro, A., Postel-Vinay, S. C., Gainor, J. F., Johnson, M. L., Dietrich, J., James, L. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30680-0 · Cited by 667
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Shaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., Novello, S., Bearz, A., Gautschi, O. P., Mok, T. S. K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30339-x · Cited by 576
Self-citation
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 473
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018
Ettinger, D. S., Aisner, D. L., Wood, D. E., Akerley, W., Bauman, J. R., Chang, J. Y., Chirieac, L. R., D’Amico, T. A., Dilling, T. J., Dobelbower, M. C., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0062 · Cited by 469
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Hanna, N. H., Schneider, B. J., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03022 · Cited by 467
Brain malignancies: Glioblastoma and brain metastases
Lah, T. T., Novak, M., & Breznik, B. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.010 · Cited by 451
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
Drilon, A. E. D. C., Hu, Z. I., Lai, G. G. Y., & Tan, D. S. W. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.175 · Cited by 413
Self-citation
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer
Solomon, B., Kim, D., Wu, Y.-L. L. C., Nakagawa, K., Mekhail, T. M., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Tang, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.4794 · Cited by 408
Self-citation
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
Shaw, A. T., Solomon, B., Besse, B., Bauer, T. M., Lin, C., Soo, R. A., Riely, G. J., Ou, S. I., Clancy, J. S., Li, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02236 · Cited by 391
Self-citation
Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment
Alduais, Y., Zhang, H., Fan, F., Chen, J., & Chen, B. (2023) · Medicine · doi:10.1097/md.0000000000032899 · Cited by 389
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK -Positive Lung Cancer
Lin, J. J., Zhu, V. W., Yoda, S., Yeap, B. Y., Schrock, A. B., Dagogo‐Jack, I., Jessop, N. A., Jiang, G. Y., Le, L. P., Gowen, K. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.2294 · Cited by 351
Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance
Schram, A. M., Chang, M. T., Jonsson, P., & Drilon, A. E. D. C. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.127 · Cited by 331
Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer
Yoda, S., Lin, J. J., Lawrence, M. S., Burke, B. J., Friboulet, L., Langenbucher, A., Dardaei, L., Prutisto-Chang, K., Dagogo-Jack, I., Timofeevski, S., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1256 · Cited by 322
Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?
Recondo, G., Facchinetti, F., Olaussen, K. A., Besse, B., & Friboulet, L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0081-4 · Cited by 321
Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
Chevallier, M., Borgeaud, M., Addeo, A., & Friedlaender, A. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i4.217 · Cited by 332
Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
Gadgeel, S. M., Peters, S., Mok, T. S. K., Shaw, A. T., Kim, D. W., Ou, S. I., Pérol, M., Wrona, A., Novello, S., Rosell, R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy405 · Cited by 322
Lung cancer in patients who have never smoked — an emerging disease
LoPiccolo, J., Gusev, A., Christiani, D. C., & Janne, P. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00844-0 · Cited by 320
A comprehensive review of protein kinase inhibitors for cancer therapy
Kannaiyan, R., & Mahadevan, D. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1527688 · Cited by 313
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Hanna, N. H., Robinson, A. G., Temin, S., Baker, S., Brahmer, J. R., Ellis, P. M., Gaspar, L. E., Haddad, R. Y., Hesketh, P. J., Jain, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03570 · Cited by 307
Receptor Tyrosine Kinase-Targeted Cancer Therapy
Yamaoka, T., Kusumoto, S., Ando, K., Ohba, M., & Ohmori, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113491 · Cited by 297
Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 294
Self-citation
ALK‐ rearrangement in non‐small‐cell lung cancer (NSCLC)
Du, X., Shao, Y., Qin, H., Tai, Y., & Gao, H. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12613 · Cited by 299
Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study
Zhou, C., Kim, S.-W., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J., Cheng, Y., Lee, S., Bu, L., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30053-0 · Cited by 275
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis
Planchard, D., Besse, B., Groen, H. J. M., Hashemi, S. M. S., Mazières, J., Kim, T. M., Quoix, É., Souquet, P.-J., Barlési, F., Baik, C. S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.08.011 · Cited by 278
Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non–Small-Cell Lung Cancer
Gainor, J. F., Tseng, D., Yoda, S., Dagogo‐Jack, I., Friboulet, L., Lin, J. J., Hubbeling, H., Dardaei, L., Farago, A. F., Schultz, K. R., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00063 · Cited by 271
Recent Advances in Targeting ROS1 in Lung Cancer
Lin, J. J., & Shaw, A. T. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.08.002 · Cited by 267
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 246
Clinical development of targeted and immune based anti-cancer therapies
Seebacher, N. A., Stacy, A. E., Porter, G., & Merlot, A. M. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1094-2 · Cited by 241
Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions
Aizer, A. A., Lamba, N., Ahluwalia, M. S., Aldape, K., Boire, A. A., Brastianos, P. K., Brown, P. D., Camidge, D. R., Chiang, V., Davies, M. A., et al. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac118 · Cited by 217
Precision Management of Advanced Non–Small Cell Lung Cancer
Yang, C., Yang, J. C., & Yang, P. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-051718-013524 · Cited by 209
MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Dagogo‐Jack, I., Yoda, S., Lennerz, J. K., Langenbucher, A., Lin, J. J., Rooney, M. M., Prutisto-Chang, K., Oh, A., Adams, N. A., Yeap, B. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3906 · Cited by 207
Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK)
Powell, C. E., Gao, Y., Tan, L., Donovan, K. A., Nowak, R. P., Loehr, A., Bahcall, M., Fischer, E. S., Jänne, P. A., George, R. E., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01655 · Cited by 198
Small molecule inhibitors targeting the cancers
Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 208
Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer
Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M. A., Michels, S., Nogova, L., Fassunke, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy333 · Cited by 197
Self-citation
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
ALK-positive lung cancer: a moving target
Schneider, J. L., Lin, J. J., & Shaw, A. T. (2023) · Nature Cancer · doi:10.1038/s43018-023-00515-0 · Cited by 194
Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study
Horn, L., Infante, J. R., Reckamp, K. L., Blumenschein, G. R., Leal, T. A. B., Waqar, S. N., Gitlitz, B. J., Sanborn, R. E., Whisenant, J. G., Du, L., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2398 · Cited by 190
Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies
Davis, J. S., Ferreira, D., Paige, E. K., Gedye, C. A., & Boyle, M. (2020) · Clinical Microbiology Reviews · doi:10.1128/cmr.00035-19 · Cited by 191
Management of Brain Metastases in Non–Small-Cell Lung Cancer
Ernani, V., & Stinchcombe, T. E. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00357 · Cited by 189
Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non–Small Cell Lung Cancer
Wu, Y.-L. L. C., Lü, S., Lü, Y., Zhou, J., Shi, Y., Sriuranpong, V., Ho, J., Ong, C. K., Tsai, C., Chung, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.06.012 · Cited by 179
Self-citation
ASCEND-8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low-Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)
Cho, B. C., Kim, D., Bearz, A., Laurie, S. A., McKeage, M. J., Borra, G., Park, K., Kim, S.-W., Ghosn, M. G., Ardizzoni, A., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.005 · Cited by 172
Targeting minimal residual disease: a path to cure?
Luskin, M. R., Murakami, M. A., Manalis, S. R., & Weinstock, D. M. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.125 · Cited by 179
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)
Majem, M., Juan, Ó., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García‐Campelo, R., García, Y. G., Guirado, M., & Provencio, M. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-018-1978-1 · Cited by 177
Clinical Management of Adverse Events Associated with Lorlatinib
Bauer, T. M., Felip, E., Solomon, B., Thurm, H. C., Peltz, G., Chioda, M. D., & Shaw, A. T. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0380 · Cited by 173
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer
Horn, L., Whisenant, J. G., Wakelee, H. A., Reckamp, K. L., Qiao, H., Leal, T. A. B., Du, L., Hernandez, J., Huang, V., Blumenschein, G. R., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.003 · Cited by 170
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
Padinharayil, H., Varghese, J., John, M. C., Rajanikant, G. K., Wilson, C. M., Al-Yozbaki, M., Renu, K., Dewanjee, S., Sanyal, R., Dey, A., et al. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.07.023 · Cited by 172
Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?
Pinto, J. A., Vallejos, C. S., Raez, L. E., Mas, L. A., Ruiz, R., Torres-Román, J. S., Morante, Z., Araujo, J. M., Gómez, H., Aguilar, A., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000344 · Cited by 167
Mechanisms and Therapy for Cancer Metastasis to the Brain
Franchino, F., Rudà, R., & Soffietti, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00161 · Cited by 159
Emerging therapies for non-small cell lung cancer
Zhang, C., Leighl, N. B., Wu, Y.-L. L. C., & Zhong, W. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0731-8 · Cited by 158
Self-citation
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Dagogo‐Jack, I., Rooney, M. M., Lin, J. J., Nagy, R. J., Yeap, B. Y., Hubbeling, H., Chin, E. N., Ackil, J., Farago, A. F., Hata, A. N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1436 · Cited by 151
Personalized therapy for lung cancer: striking a moving target
Pakkala, S., & Ramalingam, S. S. (2018) · JCI Insight · doi:10.1172/jci.insight.120858 · Cited by 154
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV
Akamatsu, H., Ninomiya, K., Kenmotsu, H., Morise, M., Daga, H., Goto, Y., Kozuki, T., Miura, S., Sasaki, T., Tamiya, A., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01431-z · Cited by 148
Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non–Small Cell Lung Cancer
Pacheco, J. M., Gao, D., Smith, D. E., Purcell, T., Hancock, M. J., Bunn, P. A., Robin, T. P., Liu, A. J., Karam, S. D., Gaspar, L. E., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.014 · Cited by 147
Role and targeting of anaplastic lymphoma kinase in cancer
Corte, C. M. D., Viscardi, G., Liello, R. D., Fasano, M., Martinelli, E., Troiani, T., Ciardiello, F., & Morgillo, F. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0776-2 · Cited by 147
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
Solomon, B., Bauer, T. M., Ou, S. I., Liu, G., Hayashi, H., Bearz, A., Penkov, K., Wu, Y.-L. L. C., Arrieta, O. G., Jassem, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02278 · Cited by 145
Self-citation
Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials
Camidge, D. R., Kim, D., Tiseo, M., Langer, C. J., Ahn, M., Shaw, A. T., Huber, R. M., Hochmair, M. J., Lee, K. H., Bazhenova, L. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.5841 · Cited by 143
Self-citation
Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
Dantoing, E., Piton, N., Salaün, M., Thiberville, L., & Guisier, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126288 · Cited by 149
Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial
Yang, Y., Zhou, J., Zhou, J., Feng, J., Zhuang, W., Chen, J., Zhao, J., Zhong, W., Zhao, Y., Zhang, Y., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30252-8 · Cited by 140
Targeted Therapy for Cancers: From Ongoing Clinical Trials to FDA-Approved Drugs
Choi, H. Y., & Chang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713618 · Cited by 143
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK)
Kong, X., Pan, P., Sun, H., Xia, H., Wang, X., Li, Y., & Hou, T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00446 · Cited by 135
Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
Coleman, N., Hong, L., Zhang, J., Heymach, J. V., Hong, D. S., & Le, X. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100319 · Cited by 136
The Evolving Modern Management of Brain Metastasis
Fecci, P. E., Champion, C. D., Hoj, J. P., McKernan, C., Goodwin, C. R., Kirkpatrick, J. P., Anders, C. K., Pendergast, A. M., & Sampson, J. H. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1624 · Cited by 129
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 130
The clinical utility of tumor mutational burden in non-small cell lung cancer
Greillier, L., Tomasini, P., & Barlési, F. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.08 · Cited by 123
Tissue and Blood Biomarkers in Lung Cancer: A Review
Duffy, M. J., & O'Byrne, K. J. (2018) · Advances in clinical chemistry · doi:10.1016/bs.acc.2018.05.001 · Cited by 124
Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
Gregg, J. P., Li, T., & Yoneda, K. Y. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.04.14 · Cited by 124
Rare molecular subtypes of lung cancer
Harada, G., Yang, S., Cocco, E., & Drilon, A. E. D. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00733-6 · Cited by 124
Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration
Hilal, T., Sonbol, M. B., & Prasad, V. K. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0167 · Cited by 121
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Bauer, T. M., Shaw, A. T., Johnson, M. L., Navarro, A., Gainor, J. F., Thurm, H. C., Pithavala, Y. K., Abbattista, A., Peltz, G., & Felip, E. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00702-4 · Cited by 122
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 119
Systemic treatment of brain metastases in non-small cell lung cancer
Page, S., Milner-Watts, C., Perna, M., Janžič, U., Vidal, N., Kaudeer, N., Ahmed, M., McDonald, F., Locke, I., Minchom, A. R., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.03.006 · Cited by 118
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Guo, H., Zhang, J., Qin, C., Yan, H., Liu, T., Hu, H., Tang, S., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11203200 · Cited by 123
The Resistance Mechanisms and Treatment Strategies for ALK-Rearranged Non-Small Cell Lung Cancer
Pan, Y., Deng, C., Qiu, Z., Cao, C., & Wu, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.713530 · Cited by 119
Advances in Targeted Therapy and Immunotherapy for Non-small Cell Lung Cancer Based on Accurate Molecular Typing
Dong, J., Li, B., Lin, D. C.-C., Zhou, Q., & Huang, D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00230 · Cited by 115
Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
König, D., Prince, S. S., & Rothschild, S. I. (2021) · Cancers · doi:10.3390/cancers13040804 · Cited by 118

PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)
de Castro, G., Tan, D. S.-W., Crinò, L., Wu, Y.-L. L. C., Paz-Ares, L. G., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D. L., Yu, C., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.008 · Cited by 12
Self-citation
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Shaw, A. T., Kim, T. M., Crinò, L., Gridelli, C., Kiura, K., Liu, G., Novello, S., Bearz, A., Gautschi, O. P., Mok, T. S. K., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30339-x · Cited by 576
Self-citation
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
Tan, D. S. W., Geater, S. L., Yu, C., Tsai, C., Hsia, T., Chen, J., Lin, M., Lü, Y., Sriuranpong, V., Yang, C., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100131 · Cited by 11
Self-citation
First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Tan, D. S. W., Geater, S. L., Yu, C., Tsai, C., Hsia, T., Zhou, J., Chen, J., Lin, M. C., Yu, P., He, J., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz259.016 · Cited by 3
Self-citation
Ceritinib is superior to frontline chemotherapy
Sidaway, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.20 · Cited by 1

Authors: Soria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., Hochmair, M., Cortot, A. B., Tsai, C.-M., Moro-Sibilot, D., Campelo, R. G., McCulloch, T., Sen, P., Dugan, M., Pantano, S., Branle, F., Massacesi, C., & de Castro, G.
Affiliations: Université Paris-Sud (FR)
National Cancer Centre Singapore (SG)
Azienda Ospedaliera di Perugia (IT)
Guangdong General Hospital (CN)
Universidad Complutense de Madrid (ES)
University Hospital Cologne (DE)
Songklanagarind Hospital (TH)
Azienda Ospedaliera San Gerardo (IT)
National Taiwan University Hospital (TW)
Otto Wagner Hospital (AT)
Centre Hospitalier Universitaire de Lille (FR)
Taipei Veterans General Hospital (TW)
Universidade da Coruña (ES)
Novartis (Switzerland) (CH)
Corresponding author: Soria, Jean-Charles
ORCID: Soria, Jean-Charles
Tan, Daniel S W
Chiari, Rita
Wu, Yi-Long
Paz-Ares, Luis
Geater, Sarayut L
Cortinovis, Diego
Yu, Chong-Jen
Hochmair, Maximillian
Cortot, Alexis B
Tsai, Chun-Ming
Campelo, Rosario G
Branle, Fabrice
Venue: The Lancet
Publisher: Elsevier BV
Published: 2017-03
Volume: 389
Issue: 10072
Pages: 917-929
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(17)30123-x
OpenAlex: W2581996620
Cited by: 1,151
References: 26
Citations by year: 2026: 38 · 2025: 73 · 2024: 98 · 2023: 123 · 2022: 142 · 2021: 128 · 2020: 139 · 2019: 146 · 2018: 168 · 2017: 94
FWCI: 123.94
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ceritinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, first-line therapy, platinum-based chemotherapy, pemetrexed, progression-free survival, targeted therapy, adverse events, diarrhea, elevated liver enzymes, brain metastases, treatment safety and efficacy comparison, WHO performance status
MeSH terms: Pemetrexed, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cisplatin, Female, Humans, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Sulfones, Carboplatin, Treatment Outcome, Disease-Free Survival, Kaplan-Meier Estimate, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks